Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39,550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Arbaclofen in fragile X syndrome: results of phase 3 trials.
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL. Berry-Kravis E, et al. Among authors: wang p. J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616094 Free PMC article.
Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.
Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. Berry-Kravis EM, et al. Among authors: wang pp. Sci Transl Med. 2012 Sep 19;4(152):152ra127. doi: 10.1126/scitranslmed.3004214. Sci Transl Med. 2012. PMID: 22993294 Clinical Trial.
Outcome measures for clinical trials in fragile X syndrome.
Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK; Outcome Measures Working Groups. Berry-Kravis E, et al. J Dev Behav Pediatr. 2013 Sep;34(7):508-22. doi: 10.1097/DBP.0b013e31829d1f20. J Dev Behav Pediatr. 2013. PMID: 24042082 Free PMC article.
STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.
Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. Erickson CA, et al. Among authors: wang pp. J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z. J Autism Dev Disord. 2014. PMID: 24272415 Clinical Trial.
Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.
Chatham CH, Taylor KI, Charman T, Liogier D'ardhuy X, Eule E, Fedele A, Hardan AY, Loth E, Murtagh L, Del Valle Rubido M, San Jose Caceres A, Sevigny J, Sikich L, Snyder L, Tillmann JE, Ventola PE, Walton-Bowen KL, Wang PP, Willgoss T, Bolognani F. Chatham CH, et al. Among authors: wang pp. Autism Res. 2018 Feb;11(2):270-283. doi: 10.1002/aur.1874. Epub 2017 Sep 21. Autism Res. 2018. PMID: 28941213 Free PMC article.
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S. Berry-Kravis EM, et al. Among authors: wang pp. Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8. Nat Rev Drug Discov. 2018. PMID: 29217836 Free PMC article. Review.
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities.
Krishnan ML, Berry-Kravis E, Capal JK, Carpenter R, Gringras P, Hipp JF, Miller MT, Mingorance A, Philpot BD, Pletcher MT, Rotenberg A, Tjeertes J, Wang PP, Willgoss T, de Wit MC, Jeste SS. Krishnan ML, et al. Among authors: wang pp. Nat Rev Drug Discov. 2021 Sep;20(9):653-654. doi: 10.1038/d41573-021-00085-9. Nat Rev Drug Discov. 2021. PMID: 34002058 No abstract available.
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1.
Parellada M, San José Cáceres A, Palmer M, Delorme R, Jones EJH, Parr JR, Anagnostou E, Murphy DGM, Loth E, Wang PP, Charman T, Strydom A, Arango C. Parellada M, et al. Among authors: wang pp. Front Psychiatry. 2021 Aug 24;12:701729. doi: 10.3389/fpsyt.2021.701729. eCollection 2021. Front Psychiatry. 2021. PMID: 34504446 Free PMC article.
A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders.
Díaz-Caneja CM, State MW, Hagerman RJ, Jacquemont S, Marín O, Bagni C, Umbricht D, Simonoff E, de Andrés-Trelles F, Kaale A, Pandina G, Gómez-Mancilla B, Wang PP, Cusak J, Siafis S, Leucht S, Parellada M, Loth E, Charman T, Buitelaar JK, Murphy D, Arango C. Díaz-Caneja CM, et al. Among authors: wang pp. Eur Neuropsychopharmacol. 2021 Jul;48:49-88. doi: 10.1016/j.euroneuro.2021.02.020. Epub 2021 Mar 27. Eur Neuropsychopharmacol. 2021. PMID: 33781629 Free article. Review.
39,550 results
You have reached the last available page of results. Please see the User Guide for more information.